RE:Price actionboazklinghorn wrote: Good news is every time the price gets past 60 the bid gets hit hard so without some kind of news we are going to be in the 50s or maybe lower come AGM day. Shareholder value baby! Coincidentally today's shareholder value is exactly the same shareholder value as we had in April 2016. 7 freaking years ago and it will be less come AGM day. Dont forget to vote for the man who brought you this fantastic return.
Everyone sees the price. Why not write up a post about the fibrosis opportunity that is before a clinical trial decision. Will it be a stand alone? What's the potential value? What evidence supports CZO's path?
With the potential imminent start of the avenanthramide clinical trial why not write up a deep dive into this asset and its potential and scientific support? Avenanthramide is the reason Gilles joined this company. The trial is about to begin. Let's see your full analysis.
“The commencement of this study represents a noteworthy milestone in the development of our avenanthramide program and could be the most significant transformational step we have taken to date in executing on our strategy to expand Ceapro’s business model towards becoming a biopharmaceutical company with the potential to provide an innovative product into very large markets." News release